BioPharma
Sanofi Puts Up $125M to Partner on Oral Drug That Could Be Dupixent’s Successor
Sanofi is interested in Recludix Pharma’s approach to treating inflammation with an oral small molecule that targets a protein thought to be undruggable. If it works, the drug could have safety and dosing advantages over currently available biologic drugs, including blockbuster Sanofi drug Dupixent.
Amarin Restructures, Charting Course That Braces for Generic Competition
The restructuring of cardiovascular drugmaker Amarin means the layoff of about 30% of staff. Sales of Vascepa, the company’s only commercialized product, have suffered as generic versions gain traction in the market.
TriNet Pharma Highlights the Rise of the Medical Science Liaison and Honors Legacy of Its Founder
For those who knew Bryan Vaughan, the late founder of TriNet Pharma, he was an […]
Here’s Why Novartis Is Paying $500M to Acquire a Preclinical RNA Startup
Novartis’s acquisition of DTx Pharma brings a lead program for a rare disease with no FDA-approved therapies. But the deal could also help the pharma giant bring new RNA therapies to new places in the body, a top Novartis executive explained.
Pfizer, Flagship Team Up in $100M R&D Pact: 10 New Drugs for Unmet Needs
Pfizer and Flagship Pioneering are partnering in a drug research alliance leveraging the capabilities of the more than 40 biotech startups in the venture capital firm’s portfolio. The new partners aim to develop drugs for unmet needs, including those in broad patient populations.
FDA Approval of RSV Drug Gives Infants and Toddlers Long-Lasting Protection
AstraZeneca and Sanofi drug Beyfortus is now FDA approved for preventing respiratory problems from RSV infection in infants and toddlers. Antibody engineering enables the drug to last longer in the body, providing protective effects for potentially the entire RSV season.
Eli Lilly Strengthens the Case for Going Early in Alzheimer’s Treatment
Alzheimer’s disease patients in the earliest stages of their disease benefited the most from Eli Lilly drug donanemab, which is expected to receive an FDA decision by the end of 2023. Full results from the drug’s pivotal study were presented during the during the Alzheimer’s Association International Conference.
Startup Tenpoint Lands $70M to Bring Vision-Restoring Cell Therapy to the Eye
Tenpoint Therapeutics’ name refers to the time it takes for an image to hit the retina and be processed by the brain. The regenerative medicine startup is developing cell therapies it hopes restore that vision capability for patients with degenerative eye disorders.
Two Biotechs Break the IPO Dry Spell, Raising $385M Combined
Inflammation and immunology biotech Apogee Therapeutics and Sagimet Biosciences, a company developing a drug for the fatty liver disease NASH, are the latest biotech companies to join the public markets. Both companies upsized their IPOs, raising cash for clinical trials.
FDA Nod Makes Perrigo’s Opill the First Oral Contraceptive to Switch to OTC Use
FDA approval of Opill makes it the first oral contraceptive that may be used without a prescription. Clinicians say over-the-counter availability will lower barriers to access to a key component of reproductive healthcare.
Your Thought Leaders Should Be Thought-Provoking. Here’s How to Make It Happen
它需要蒂姆e to develop a cogent thought leadership platform. Julia Fuller, Executive Vice President at Ford Hutman Media provides insights, tips, and strategies for companies and industry leaders looking to get ahead and define emerging trends.
Artificial Intelligence,BioPharma
Nvidia’s $50M Recursion Investment Starts Alliance to Scale Up in AI Drug Discovery
Nvidia’s investment isn’t just working capital for Recursion Pharmaceuticals’ technology-driven drug discovery research. Recursion says it will get more computing power as well as the possibility of joining forces with Nvidia in research.
Devices & Diagnostics,BioPharma
Europe Imposes Maximum Fine on Illumina for Early Grail Acquisition
Illumina must pay a €432 million fine for closing its Grail acquisition before the European Commission finished its inquiry into the tie-up. The penalty is the maximum amount the regulator can impose on a company for breaching European merger rules.
With End of Alliance, Novartis Walks Away From Once Hot Cancer Target
Novartis and BeiGene ended their partnership on a cancer immunotherapy for a target called TIGIT. Though BeiGene describes the termination as mutual, it comes before Novartis would need to pump more money into the alliance even as questions linger about TIGIT as a cancer target.
Devices & Diagnostics,BioPharma
FDA Authorizes Better Therapeutics Mobile App for Treating Type 2 Diabetes
Better Therapeutics prescription digital therapeutic, AspyreRx, received De Novo FDA authorization for type 2 diabetes. The mobile app digitizes and personalizes cognitive behavioral therapy.
RA Capital Leads $150M Financing for Septerna and Lead Drug With Oral Edge in Rare Hormone Disease
Septerna Therapeutics’ Series B financing will support plans to reach the clinic with a pill for a rare disease whose only approved therapy is a Takeda Pharmaceutical drug that’s leaving the market. Potential rival therapies are all injectables.
BioPharma,Hospitals,Legal,Payers,Policy
Hospitals Have Concerns About CMS’ Proposed $9B Lump Sum Payment for Illegal 340B Cuts
CMS包干此外最近提出了一个90亿美元t to remedy illegal payment cuts for 340B drugs from 2018 to 2022. In general, hospital groups have reacted positively to the fact that 340B providers will receive lump sum payments but have expressed concern about CMS’ methods for maintaining budget neutrality with this plan.
Promoted
Enhancing Efficiency in your Practices: Unleashing the Power of Greenway Health’s Optimization Services
Resolve your healthcare information technology concerns by optimizing your technology, boosting workflows, improving staff productivity, and driving revenue.
Promoted
What is the ROI for Conversational AI in Patient Access?
Health systems need to turn their attention to technology that can improve staff retention by reducing employee burnout, according to HCA Divisional CIO Andy Draper. Here’s a look at what Parlance is doing to realize ROI with conversational AI.
